Table 2 Clinical and demographic features of the metabotypes identified thought KODAMA analysis
From: Inflammatory metabolic profile of South African patients with prostate cancer
Feature | Metabotype I | Metabotype II | Metabotype III | Metabotype IV | p value |
|---|---|---|---|---|---|
NCCN classification, n (%) |  |  |  |  | 1.14 × 10−1 |
 Very low | 1 (33.3) | 0 (0.0) | 1 (7.1) | 0 (0.0) |  |
 Low | 0 (0.0) | 1 (10.0) | 1 (7.1) | 1 (14.3) |  |
 Intermediate | 2 (66.7) | 4 (40.0) | 3 (21.4) | 0 (0.0) |  |
 High | 0 (0.0) | 3 (30.0) | 4 (28.5) | 0 (0.0) |  |
 Very high | 0 (0.0) | 2 (20.0) | 5 (35.7) | 5 (71.4) |  |
 Metastatic | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (14.3) |  |
Gleason score, n (%) |  |  |  |  | 9.00 × 10−2 |
 3 + 3 | 1 (33.3) | 1 (10.0) | 5 (35.7) | 1 (14.3) |  |
 3 + 4 | 1 (33.3) | 4 (40.0) | 6 (42.9) | 0 (0.0) |  |
 4 + 3 | 1 (33.3) | 1 (10.0) | 0 (0.0) | 0 (0.0) |  |
 3 + 5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (14.3) |  |
 4 + 5 | 0 (0.0) | 4 (40.0) | 3 (21.4) | 0 (0.0) |  |
 5 + 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (28.6) |  |
 5 + 5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (42.9) |  |
Age, median [95% CI] | 71 [64 74] | 68 [56 90] | 65 [51 85] | 74 [59 78] | 9.49 × 10−1 |
Ancestry, n(%) |  |  |  |  | 4.11 × 10−1 |
 Black | 1 (33.3) | 1 (10.0) | 2 (14.3) | 3 (42.9) |  |
 Mixed ancestry | 1 (33.3) | 7 (70.0) | 11 (78.6) | 2 (28.6) |  |
 White | 1 (33.3) | 2 (20.0) | 1 (7.1) | 2 (28.6) |  |
PSA, median [95% CI] | 9 [3 9] | 18 [5 233] | 25 [5 126] | 738 [26 5000] | 5.89 × 10−3 |
Diabetes, n (%) |  |  |  |  | 8.85 × 10−2 |
 No | 1 (33.3) | 7 (70.0) | 13 (92.9) | 7 (100.0) |  |
 Yes | 2 (66.7) | 3 (30.0) | 1 (7.1) | 0 (0.0) |  |
Hypertension, n (%) |  |  |  |  | 1.18 × 10−1 |
 No | 0 (0.0) | 8 (80.0) | 9 (64.3) | 6 (85.7) |  |
 Yes | 3 (100.0) | 2 (20.0) | 5 (35.7) | 1 (14.3) |  |
Smoker, n (%) |  |  |  |  | 4.37 × 10−1 |
 No | 2 (66.7) | 8 (80.0) | 9 (64.3) | 7 (100.0) |  |
 Yes | 1 (33.3) | 2 (20.0) | 5 (35.7) | 0 (0.0) |  |